Clinical Trial Update: Single Agent Abraxane as Second Line Therapy in Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating single-agent Abraxane as second-line therapy for bladder cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Transitional Cell Carcinoma | Phase 2 | Status: COMPLETED